G-protein coupled receptors are highly utilized cell receptors in the body. They are accessible at the cell surface many drugs sold in the U.S. target them. Uppsala University and the University of Copenhagen have mapped these drugs and tested them in clinical trials. This has been published in the journal Nature Reviews Drug Discovery. The mapping has revealed how a large number of receptors have been targeted by this type of drugs. Advantage of new scientific principles has been employed to achieve higher safety through cellular signaling and more specific target interactions.
On comparing the drugs available in the market with those that are undergoing clinical trials, a PhD student at the Department of Drug Design and Pharmacology said that we can see the future trends and based on a number of parameters it can be seen that the new drugs targeting the receptors have a more precise effect. They are also more complex and have much less side effects. Of late, researchers have also learned more about how G protein-coupled receptors are built and how they function. They have been able to learn more mostly through 3D atomic structures and this knowledge has been translated into drug development. The mapping also shows that the future drugs can affect few receptors and be more specific. This in turn will result in reduced side effects.
The shift from small chemical drugs to more complex biological protein drugs is increasing. These drugs can fine tune their effect and be more precise. The mapping has shown that there is a great potential for research in these receptors. Many G protein coupled receptors do not have a drug targeting them, giving a considerable untapped potential.